Keywords: alexion, submits, soliris, nda, japan, usa, pharmaceuticals

Alexion submits Soliris NDA in Japan

Article | 16 April 2009

Print This

The USA's Alexion Pharmaceuticals has submitted a New Drug Application for Soliris (eculizumab), as a treatment for patients with paroxysmal ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in